MICB Genetic Variants and Its Protein Soluble Level Are Associated with the Risk of Chronic GvHD and CMV Infection after Allogeneic HSCT
By:
Jagoda Siemaszko, Marta Dratwa, Agnieszka Szeremet, Maciej Majcherek, Anna Czyż, Małgorzata Sobczyk-Kruszelnicka, Wojciech Fidyk, Iwona Solarska, Barbara Nasiłowska-Adamska, Patrycja Skowrońska, Maria Bieniaszewska, Agnieszka Tomaszewska, Grzegorz W. Basak, Sebastian Giebel, Tomasz Wróbel and Katarzyna Bogunia-Kubik
DOI: https://doi.org/10.2478/aite-2024-0012 | Journal eISSN: 1661-4917
Language: English
Submitted on: Feb 20, 2024
Accepted on: May 13, 2024
Published on: Jun 7, 2024
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2024 Jagoda Siemaszko, Marta Dratwa, Agnieszka Szeremet, Maciej Majcherek, Anna Czyż, Małgorzata Sobczyk-Kruszelnicka, Wojciech Fidyk, Iwona Solarska, Barbara Nasiłowska-Adamska, Patrycja Skowrońska, Maria Bieniaszewska, Agnieszka Tomaszewska, Grzegorz W. Basak, Sebastian Giebel, Tomasz Wróbel, Katarzyna Bogunia-Kubik, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.